Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $799 Million
- Q1 2024
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 8,020,136 shares of DYN stock, worth $256 Million. This represents 28.49% of its overall portfolio holdings.
Number of Shares
8,020,136
Previous 9,885,449
18.87%
Holding current value
$256 Million
Previous $131 Million
73.18%
% of portfolio
28.49%
Previous 20.67%
Shares
4 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Fcpm Iii Services B.V. Naarden, P77.85MShares$250 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$172 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$145 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$136 Million0.02% of portfolio
-
State Street Corp Boston, MA4.19MShares$134 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.65B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...